Compare AMN & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMN | MPLT |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2001 | 2025 |
| Metric | AMN | MPLT |
|---|---|---|
| Price | $46.18 | $7.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $36.57 | $26.54 |
| AVG Volume (30 Days) | ★ 870.1K | 339.8K |
| Earning Date | 11-05-2026 | 12-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.58 | ★ 82.39 |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $1,988,454,000.00 | N/A |
| Revenue This Year | $22.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.20 | ★ N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $14.97 | $7.44 |
| 52 Week High | $49.62 | $40.43 |
| Indicator | AMN | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 71.41 | 27.46 |
| Support Level | $31.09 | N/A |
| Resistance Level | N/A | $8.58 |
| Average True Range (ATR) | 2.25 | 0.55 |
| MACD | 0.32 | 0.09 |
| Stochastic Oscillator | 75.55 | 3.82 |
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. A majority of its revenue is generated from the Nurse and Allied Solutions segment, which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.